LT2014140A - New recombinant antibody against human carbonic anhydrase xii - Google Patents
New recombinant antibody against human carbonic anhydrase xiiInfo
- Publication number
- LT2014140A LT2014140A LT2014140A LT2014140A LT2014140A LT 2014140 A LT2014140 A LT 2014140A LT 2014140 A LT2014140 A LT 2014140A LT 2014140 A LT2014140 A LT 2014140A LT 2014140 A LT2014140 A LT 2014140A
- Authority
- LT
- Lithuania
- Prior art keywords
- recombinant antibody
- carbonic anhydrase
- anhydrase xii
- produced
- antibody
- Prior art date
Links
Landscapes
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Peptides Or Proteins (AREA)
Abstract
A new recombinant antibody that targets transmembrane enzyme carbonic anhydrase XII was produced. The expression of the enzyme increases in certain types of cancer cells. Recombinant antibody produced is a new protein, which so far has not been described in scientific literature. First, cell line (hybridomas) producing monoclonal antibody to carbonic anhydrase XII was developed. Copy DNA sequences encoding an immunoglobulin variable regions were cloned from hybridoma cells, recombinant plasmids were created and recombinant antibody expression was attained. Well-known methods, such as hybridoma technology, genetic engineering, protein purification, immunochemical analysis were used for antibody development. Recombinant antibody produced may be applied in medical and biopharmaceutical branches due to capacity to inhibit growing of cancer cells containing carbonic anhydrase XII.
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
LT2014140A LT6331B (en) | 2014-12-12 | 2014-12-12 | New recombinant antibody against human carbonic anhydrase xii |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
LT2014140A LT6331B (en) | 2014-12-12 | 2014-12-12 | New recombinant antibody against human carbonic anhydrase xii |
Publications (2)
Publication Number | Publication Date |
---|---|
LT2014140A true LT2014140A (en) | 2016-06-27 |
LT6331B LT6331B (en) | 2016-11-10 |
Family
ID=56134742
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
LT2014140A LT6331B (en) | 2014-12-12 | 2014-12-12 | New recombinant antibody against human carbonic anhydrase xii |
Country Status (1)
Country | Link |
---|---|
LT (1) | LT6331B (en) |
Families Citing this family (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2018088878A2 (en) | 2016-11-14 | 2018-05-17 | 주식회사 에이프로젠케이아이씨 | Antibody binding to carbonic anhydrase and use thereof |
-
2014
- 2014-12-12 LT LT2014140A patent/LT6331B/en not_active IP Right Cessation
Also Published As
Publication number | Publication date |
---|---|
LT6331B (en) | 2016-11-10 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
EA201992670A1 (en) | METHOD FOR OBTAINING BISPECIFIC ANTIBODIES, BISPECIFIC ANTIBODIES AND THERAPEUTIC APPLICATION OF SUCH ANTIBODIES | |
MX2016015389A (en) | Antibodies binding to human and cynomolgus cd3 epsilon. | |
MX2018013738A (en) | Antibodies comprising chimeric constant domains. | |
PH12017501114A1 (en) | Anti-c5 antibodies and methods of use | |
RU2018146533A (en) | ANTIBODIES TO CD40 AND WAYS OF THEIR APPLICATION | |
GB2549632A8 (en) | Fusion protein comprising three binding domains to 5T4 and CD3 | |
RU2014148136A (en) | T-CELL COMPOSITIONS WITH LACK OF T-CELL RECEPTORS | |
PE20181054A1 (en) | HUMANIZED ANTI-CD19 ANTIBODIES AND METHODS OF USE | |
MX2017001403A (en) | Bispecific single chain antibody construct with enhanced tissue distribution. | |
EA201600276A1 (en) | ANTI-IL-17-ANTIBODIES, METHOD OF THEIR RECEIVING AND METHOD OF APPLICATION | |
GB2509260A (en) | Anti-complement C1s antibodies and uses thereof | |
EP4223874A3 (en) | Human anti-il-33 neutralizing monoclonal antibody | |
NZ708182A (en) | Bispecific t cell activating antigen binding molecules | |
MX2022014885A (en) | Anti-c5 antibodies and methods of use. | |
EP4371570A3 (en) | Treatment of igg4-related diseases with anti-cd19 antibodies crossbinding to cd32b | |
MX2016005687A (en) | Methods for enhancing immunosuppressive therapy by multiple administration of alpha beta tcr-binding polypeptide. | |
NZ630865A (en) | Anti-baff-anti-il-17 bispecific antibodies | |
GB201003701D0 (en) | System for the expression of a protein | |
EA201691548A1 (en) | EXPRESSING STRUCTURES AND METHODS FOR SELECTION OF CELL HOSPITALS EXPRESSING POLYPEPTIDES | |
TN2015000415A1 (en) | Anti-cd52 antibodies | |
PH12017500309A1 (en) | Anti-vasa antibodies, and methods of production and use thereof | |
EA202091569A1 (en) | MONOCLONAL ANTIBODIES AND METHODS OF THEIR APPLICATION | |
BR112016028538A2 (en) | glycosylated protein production process, monoclonal antibody and fusion protein production processes and fragment thereof, tnfr-fc fusion protein production process, monoclonal antibody or fusion protein production and fragment thereof | |
LT2014140A (en) | New recombinant antibody against human carbonic anhydrase xii | |
MX2022014243A (en) | St2 antigen binding protein. |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
BB1A | Patent application published |
Effective date: 20160627 |
|
FG9A | Patent granted |
Effective date: 20161110 |
|
MM9A | Lapsed patents |
Effective date: 20201212 |